公开(公告)号：US12103969B2

公开(公告)日：2024-10-01

申请号：US17266092

申请日：2018-09-25

申请人： Academia Sinica

发明人： Shie-Liang Hsieh ,  Tsung-Yu Tsai ,  An-Suei Yang ,  Chung-Ming Yu ,  Cheng-Yuan Peng

IPC分类号： C07K16/28 ,  A61P25/28 ,  A61P31/20 ,  A61K39/00

CPC分类号： C07K16/2803 ,  A61P25/28 ,  A61P31/20 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/77

摘要： Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection.

公开(公告)号：US11142795B2

公开(公告)日：2021-10-12

申请号：US16491163

申请日：2018-03-15

申请人： Academia Sinica

发明人： Shie-Liang Hsieh ,  Ya-Lang Huang ,  Tsung-Yu Tsai

IPC分类号： G01N33/53 ,  A61K38/21 ,  C12Q1/6883 ,  C12Q1/70 ,  G01N33/566 ,  G01N33/576

摘要： Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.